BXRX stock forecast
Our latest prediction for Baudax Bio Inc's stock price was made on the Aug. 20, 2021 when the stock price was at 0.51$.
In the short term (2weeks), BXRX's stock price should outperform the market by 4.71%. During that period the price should oscillate between -11.78% and +23.34%.
In the medium term (3months), BXRX's stock price should outperform the market by 34.73%. During that period the price should oscillate between -46.44% and +75.15%.
Get email alertsCreate a solid portfolio with BXRX
About Baudax Bio Inc
Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio's first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a profit of 0.71$ per share.
The book value per share is -0.21$
Three months stock forecastAug. 20, 2021
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | -358.40% | -58M | - | -38M | 0.71 | - | - | 47M | -0.21 | -50M | -1M | -51M |